Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 4/20 | 0.81 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.81 |
| ▸ | FLT4 | P35916 | 4/20 | 0.81 |
| ▸ | FLT3 | P36888 | 3/20 | 0.81 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.63 |
| ▸ | KIT | P10721 | 2/20 | 0.63 |
| ▸ | KDR | P35968 | 10/20 | 0.62 |
| ▸ | RET | P07949 | 1/20 | 0.61 |
| ▸ | KIF5B | P33176 | 1/20 | 0.61 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.59 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 3/20 | 0.58 |
| ▸ | LCK | P06239 | 2/20 | 0.58 |
| ▸ | BRAF | P15056 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4023315 | 0.94 | PDGFRB (0.75) | CSF1RPDGFRBFLT4FLT3PDGFRA | |
| SCHEMBL15607578 | 0.92 | PDGFRB (0.77) | CSF1RPDGFRBFLT4FLT3PDGFRA | |
| SCHEMBL8810873 | 0.91 | PDGFRB (0.68) | CSF1RPDGFRBFLT4FLT3PDGFRA | |
| SCHEMBL30406755 | 0.91 | CSF1R (0.68) | CSF1RPDGFRBFLT4FLT3PDGFRA | |
| SCHEMBL4466873 | 0.91 | CSF1R (0.68) | CSF1RPDGFRBFLT4FLT3PDGFRA | |
| SCHEMBL23158591 | 0.89 | CSF1R (0.66) | CSF1RPDGFRBFLT4FLT3PDGFRA | |
| SCHEMBL18158553 | 0.87 | KDR (0.70) | CSF1RPDGFRBFLT4FLT3PDGFRA | |
| SCHEMBL7452950 | 0.87 | PDGFRB (0.66) | CSF1RPDGFRBFLT4FLT3PDGFRA | |
| SCHEMBL13680204 | 0.87 | KDR (0.73) | CSF1RPDGFRBFLT4FLT3PDGFRA | |
| SCHEMBL10296331 | 0.86 | IRAK1 (0.68) | CSF1RPDGFRBFLT4FLT3PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1638954-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | disclosed |
| WO-2004085425-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC (US) | 2004-10-07 | — | — | WO | disclosed |
| EP-0782570-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-07-09 | — | — | EP | disclosed |
| WO-1996009294-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209892-A1 | Heterocyclic compounds and methods of use | VHL, NQO1, HPGDS | CSF1R 2626/4885PDGFRB 641/4885FLT4 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.